ASSOCIATION BETWEEN SPECIFIC FEATURES OF GATA3 TRANSCRIPTION FACTOR EXPRESSION AND LYMPH NODE METASTASIS IN LUMINAL BREAST CANCER

Currently, the study of the markers of cell differentiation, proliferative regulators, and molecules involved in the development of drug resistance mechanisms in breast cancer is extremely important. The transcription factor GATA3 plays an essential role in the differentiation and proliferative activity of luminal breast cancer cells, being a tumor suppressor. The GATA3 positive expression is most frequently observed in invasive carcinoma of no special type. High expression of GATA3 is associated with low-grade ER-positive cancer with a favorable prognosis. Low GATA3 expression is observed in patients with high-grade and hormone receptor-negative cancer. The study of GATA3 expression is necessary for understanding the development of drug resistance mechanisms and developing approaches to overcome them as well as for determining the response to hormone therapy. Aim. The present study was undertaken to study the expression characteristics of the transcription factor GATA3 in patients with luminal breast cancer and to evaluate their relationship with the parameters of lymphogenous metastasis. Material and methods. The study included 64 patients with stage T1–4N1–3M0 invasive breast cancer. The primary tumor tissue and all removed lymph nodes were morphologically examined. The diagnosis was established according to the WHO criteria (2012). Results. Low GATA3 expression was associated with a high risk of lymph node metastases, while high GATA3 expression was associated with the absence of lymph node metastases. Heterogeneous GATA3 expression was associated with high risk of lymph node metastasis, and as a consequence, with poor prognosis. Conclusion. The relationship between the expression of GATA3 protein and lymphogenic metastasis in patients with luminal breast cancer was found.

breast cancer, transcription factor GATA3, lymph node metastasis, prognosis, drug resistance

1. Kaprin A.D., Starinsky V.V., Petrova G.V. Malignant neoplasms in Russia in 2015 (morbidity and mortality). Moscow, 2017. 250. [in Russian]

2. Cimino-Mathews A., Subhawong A.P., Illei P.B., Sharma R., Halushka M.K., Vang R., Fetting J.H., Park B.H., Argani P. GATA3 expression in breast carcinoma: utility in triple-negative, sarcomatoid, and metastatic carcinomas. Hum Pathol. 2013 Jul; 44 (7): 1341–9. doi: 10.1016/j.humpath.2012.11.003.

3. Byrne D.J., Deb S., Takano E.A., Fox S.B. GATA3 expression in triple-negative breast cancers. Histopathology. 2017 Jul; 71 (1): 63–71. doi: 10.1111/his.13187.

4. Deftereos G., Sanguino Ramirez A.M., Silverman J.F., Krishnamurti U. GATA3 immunohistochemistry expression in histologic subtypes of primary breast carcinoma and metastatic breast carcinoma cytology. Am J Surg Pathol. 2015 Sep; 39 (9): 1282–9. doi: 10.1097/ PAS.0000000000000505.

5. Gonzalez R.S., Wang J., Kraus T., Sullivan H., Adams A.L., Cohen C. GATA-3 expression in male and female breast cancers: comparison of clinicopathologic parameters and prognostic relevance. Hum Pathol. 2013 Jun; 44 (6): 1065–70. doi: 10.1016/j.humpath.2012.09.010.

6. Yoon N.K., Maresh E.L., Shen D., Elshimali Y., Apple S., Horvath S., Mah V., Bose S., Chia D., Chang H.R., Goodglick L. Higher levels of GATA3 predict better survival in women with breast cancer. Hum Pathol. 2010 Dec; 41 (12): 1794–801. doi: 10.1016/j.humpath.2010.06.010.

7. Mehra R., Varambally S., Ding L., Shen R., Sabel M.S., Ghosh D., Chinnaiyan A.M., Kleer C.G. Identification of GATA3 as a Breast Cancer Prognostic Marker by Global Gene Expression Meta-analysis. Cancer Res. 2005 Dec 15; 65 (24): 11259–64.

8. Shahi P., Wang C.Y., Chou J., Hagerling C., Gonzalez Velozo H., Ruderisch A., Yu Y., Lai M.D., Werb Z. GATA3 targets semaphorin 3B in mammary epithelial cells to suppress breast cancer progression and metastasis. Oncogene. 2017 Oct 5; 36 (40): 5567–75. doi: 10.1038/ onc.2017.165.

9. Tkocz D., Crawford N.T., Buckley N.E., Berry F.B., Kennedy R.D., Gorski J.J., Harkin D.P., Mullan P.B. BRCA1 and GATA3 corepress FOXC1 to inhibit the pathogenesis of basal-like breast cancers. Oncogene. 2012 Aug 9; 31 (32): 3667–78. doi: 10.1038/onc.2011.531.

10. Cohen H., Ben-Hamo R., Gidoni M., Yitzhaki I., Kozol R., Zilberberg A., Efroni S. Shift in GATA3 functions, and GATA3 mutations, control progression and clinical presentation in breast cancer. Breast Cancer Res. 2014 Nov 20; 16 (6): 464. doi: 10.1186/s13058-014-0464-0.

11. Hoch R.V., Thompson D.A., Baker R.J., Weigel R.J. GATA-3 is expressed in association with estrogen receptor in breast cancer. Int J Cancer. 1999 Apr 20; 84 (2): 122–8.